Facultad De Medicina Unachi página oficial

Coeliac disease is an autoimmune disorder caused by the ingestion of gluten in genetically susceptible individuals.

This new Seminar provides updated information for those who care for patients with Coeliac disease, with a focus on currently unsolved questions and research directions: https://hubs.li/Q01dxgHD0

New review by Eugene Braunwald, M.D., reviews the actions of SGLT2 inhibitors and their implications in the management of cardiovascular disease. https://nej.md/3MLuORp

New CDC study finds one in five adults ages 18–64 years and one in four ages 65 years and older who survived COVID-19 had a new condition at least 4 weeks after their COVID-19 illness that may be associated with the past illness. Regardless of age, adult COVID-19 survivors had twice the risk of developing a blood clot in the lung or a new respiratory condition.

Talk to your health care provider if you still have symptoms or develop new symptoms after a previous infection. Learn more: https://bit.ly/MMWR7121.

The answer to yesterday's question is: C.

Efgartigimod alfa, a novel immunoglobulin G1 (IgG1) Fc fragment that inhibits the neonatal Fc receptor and reduces circulating IgG antibody levels, has been under investigation for myasthenia gravis (MG) and other autoimmune disorders associated with IgG autoantibodies.

In a trial of 167 patients with generalized MG, weekly infusions of efgartigimod increased the rate of symptomatic improvement at four weeks compared with placebo. Adverse effects were mild and similar between groups with short-term follow-up. Based on these results, efgartigimod was approved by the US Food and Drug Administration for treatment of MG in patients with antiacetylcholine receptor antibodies. It will likely find use initially as an alternative steroid-sparing agent for patients unable to tolerate first-line therapies with slower time to effect.

Read What's New in . http://ow.ly/Y5v750IvltP

How do pathologic stimuli result in fibrosis and the development of calcific nodules, which compromise the biomechanical integrity of the aortic valve and lead to stenosis? https://nej.md/3u6ziek

A systematic review and meta-analysis of randomized control trials (RCTs) found that sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce hospitalizations and may reduce cardiovascular deaths among people experiencing heart failure regardless of the presence of diabetes. These findings support existing guidelines that recommend SGLT2 inhibitors for preventing incident and worsening heart failure in people with type 2 diabetes, heart failure, or both: http://ow.ly/OplM50IHL6R

🇵🇦